HomeExamplesMCP & ModelsResearchDocumentationLoginBook a demo
HomeExamplesMCP & ModelsResearchDocumentationLoginBook a demo

Syngle Therapeutics

Ownership
Private
Employees
~10
Therapeutic Areas
Neurology
Stage
Phase 2
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
AntibodyImmunotherapy

Syngle Therapeutics General Information

Syngle Therapeutics is developing antibodies against oligomeric alphasynuclein for Parkinson's disease treatment. Their lead candidate 26F1 is currently in preclinical development.

Contact Information

Website
https://www.syngletherapeutics.com/
Primary Industry
Biotech
Corporate Office
, Randstad
Netherlands

Drug Pipeline

26F1
Pre-clinical
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 2
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 3
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum

For full access to Syngle Therapeutics's pipeline data

Book a demo

Key Partnerships

Crossbeta Biosciences

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

Syngle Therapeutics Funding

No funding data available

Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view Syngle Therapeutics's complete valuation and funding history, request access »

Syngle Therapeutics Financial Metrics

See full profile
Book a demo
OverviewDrug PipelineTechnologiesPartnershipsFundingCompetitorsAnalysisPatentsLicensing Deals